First-in-Human Trial Shows PEGylated Uricase HZBio1 Is Well Tolerated and Slashes Uric Acid
A first-in-human phase 1a trial in China found that single intramuscular doses of the PEGylated recombinant uricase HZBio1 were well ...
A first-in-human phase 1a trial in China found that single intramuscular doses of the PEGylated recombinant uricase HZBio1 were well ...
A clinical trial finds that the traditional Korean formulations Bojungikgitang and Cheongsanggyeontongtang substantially raise or lower edoxaban exposure in healthy ...
A translational modelling study finds that PD-1 receptor occupancy does not predict immune activation during pembrolizumab therapy, challenging current dosing ...
Researchers are using PD-L1-targeted PET/CT imaging to directly visualise whether the immunotherapy drug atezolizumab saturates its target in tumours, offering ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine